Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
The association between Helicobacter pylori infection and insulin resistance: a systematic review..
Helicobacter. 16(2), 79-88.
(2011). Nonalcoholic fatty liver disease and polycystic ovary syndrome..
Ann Hepatol. 14(6), 941-3.
(2015). Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations..
Maturitas. 147, 19-25.
(2021). Irisin: a renaissance in metabolism?.
Metabolism. 62(8), 1037-44.
(2013). Irisin in metabolic diseases..
Endocrine. 59(2), 260-274.
(2018). Irisin in patients with nonalcoholic fatty liver disease..
Metabolism. 63(2), 207-17.
(2014). Metreleptin for the treatment of lipodystrophy: leading the way among novel therapeutics for this unmet clinical need..
Curr Med Res Opin. 38(6), 885-888.
(2022). Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name..
Metabolism. 113, 154413.
(2020). Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid..
Support Care Cancer. 17(10), 1329-30.
(2009). Comment on: Jeon et al. Helicobacter pylori Infection Is Associated With an Increased Rate of Diabetes. Diabetes Care 2012;35:520-525..
Diabetes Care. 35(7), e53; author reply e54.
(2012). Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease..
J Renin Angiotensin Aldosterone Syst. 12(4), 498-503.
(2011). Mild leukopenia following denosumab treatment in a woman with postmenopausal osteoporosis..
Endocrine. 62(2), 487-489.
(2018). Bone and fat interplay in inflammatory bowel disease: clinical implications and future perspectives..
Inflamm Bowel Dis. 20(11), E22.
(2014). Helicobacter pylori Infection: One More Contributor to Nonalcoholic Fatty Liver Disease Pathophysiology..
J Clin Gastroenterol.
(2019). Primary hyperparathyroidism and incidental multifocal metastatic papillary thyroid carcinoma in a man..
Arq Bras Endocrinol Metabol. 54(6), 578-82.
(2010). Nonalcoholic fatty future disease..
Metabolism. 65(8), 1007-16.
(2016). Serum visfatin in nonalcoholic fatty liver disease..
Ann Hepatol. 13(1), 150-1.
(2013). Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics..
Metabolism. 92, 82-97.
(2019). Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease..
Curr Obes Rep.
(2024). Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-γ agonists..
Metabolism. 66, 64-68.
(2017). Coincidental thyroid papillary microcarcinoma in a patient treated for a toxic adenoma of the thyroid..
Arch Iran Med. 14(2), 149-51.
(2011). Histological alterations following thyroid fine needle biopsy: a systematic review..
Diagn Cytopathol. 37(6), 455-65.
(2009). Cilofexor for the Treatment of Nonalcoholic Steatohepatitis.
Curr Vasc Pharmacol.
(2021). Trying to treat diabetes in Greek crisis..
Int J Clin Pract. 66(5), 515.
(2012). Denosumab treatment for juvenile Paget's disease: results from two adult patients with osteoprotegerin deficiency ("Balkan" mutation in the TNFRSF11B gene)..
J Clin Endocrinol Metab. 99(3), 703-7.
(2014).